Enzymit’s technology allows for unprecedented search of sequence space which is both expansive and focused. Protein sequence space is for even small proteins is intractable. There are over 10 possible sequence changes for any given protein. Experimental screening can only test upto
10 -10 enzyme variants in a single experiment. These experiments are extremely laborious, time consuming and not generalizable.
We Are Building a
To improve existing enzyme functionality, at a fraction of the cost and time of alternative approaches.
To invent new enzymes to address unmet market needs.
Enzyme’s 3D structures define their function (their ability to work on the desired chemical) Each chemical requires the correct shape (conformation). To build new enzymes we need more structures. There are only a limited number of known enzyme structures (gathered from experiments). Compared to the vast protein sequence data
we have obtained through various genome projects.
Protein sequence space is for even small proteins is intractable. There are over 10 possible sequence changes for any given protein
Data gathered is fed into deep learning algorithms for continuous optimization of our enzyme design pipeline
design algorithms for new
chemistry enzyme design
Novel, proprietary experimental tools for high throughput testing of enzyme variants
Co-founder, COO and VP
MSc, computational protein design - Weizmann Institute of Science.
Protein engineering and molecular biology expert.
Former Innovation Project Manager and Process Engineer at Biolojic Design.
Former Founding Scientist at IgC - led the experimental platform development.
Co-founder, CEO and
PhD, computational protein design - Weizmann Institute of Science.
Developed computational algorithms for building novel antibodies and enzymes with high accuracy and activity.
Former Analyst at Yeda R&D (WIS).
Former infantry platoon commander in the IDF.
Prof. Joseph Jacobson
Tenured professor at MIT
Head of the Molecular Machines group at the Center for Bits and Atoms at the MIT Media Lab
World expert in synthetic biology
Contributes to the scientific development of the platform
Dr. Devin Leake
Ph.D. in Molecular Biology and Biochemistry from the SUNY Stony Brook
Former head of DNA Synthesis at Ginkgo Bioworks
Has over one hundred issued patents and more than thirty publications in the area of nucleic acid biology
Head of Computational Design
MSc in bioinformatics from the Hebrew University.
An expert in bioinformatics with a specialization in machine-learning.
Founding scientists at IgC - developed novel algorithms for antibody design.
Ph.D. in Life Sciences, Ben-Gurion University
Broad scientific knowledge in the field of protein folding in-vivo, with specialization in molecular biology, molecular genetics, biochemistry, and cell biology
Former scientist at Smart Assays.
Business Development Manager
BA in Business Administration and Economics, Interdisciplinary Center Herzliya (Senior).
Former Investment Analyst at OurCrowd.
IDC Investment Management Group member.
Former IDF special forces.